Mengmeng Tang, currently the Senior Director of the Regulatory and Compliance Center at Shanghai Juncell Therapeutics Co., Ltd, holds a Bachelor of Biochemistry from Nanjing University and a Master of Biochemistry from Indiana University Bloomington. She is PMP® certified and also a Licensed Pharmacist in China.

With over 12 years of experience in biopharmaceutical research and project management, she has been responsible for a variety of tasks, including cell product development, quality control, R&D project management, clinical trial operations, and biopharmaceutical drug registration.

The autologous natural tumor-infiltrating lymphocyte (TIL) GC101 and the gene-modified TIL GC203, for which she was in charge of the drug registration, have been approved for clinical trials in China. GC101, the world's first natural TIL cell drug which neither requires high-dose lymphodepletion nor IL-2 injections, has entered the critical phase II clinical trial for melanoma. GC203 is the world's first newly developed TIL cell drug based on non-viral vectors, and has entered Phase I clinical trials for pan solid tumors.